In Some diseases, such as for inflammatory bowel disease (IBD), the problem has altered significantly over the past few decades, with a significant increase in the number of IBD individuals who are overweight and have problems with weight problems‐similar complications. Conclusions: Golimumab will not seem in a position to maintain https://www.directivepublications.org/journal-of-digestive-and-liver-diseases/